Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy—Advances through 2026
Regenerative Therapy · 2026-12 · 33 · 101150
DOI: 10.1016/j.reth.2026.101150 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Regenerative Therapy, 2026-12. Verfasst von Satoru Morimoto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Keio University Regenerative Medicine Research Center (KRM), Kanagawa, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Intractable Diseases Research Foundation, Ono Medical Research Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Keio University Regenerative Medicine Research Center (KRM), Kanagawa, Japan.
Förderung
- Japan Agency for Medical Research and Development
- Japan Intractable Diseases Research Foundation
- Ono Medical Research Foundation
- Japan Society for the Promotion of Science
- Inamori Foundation
- The Nakatomi Foundation
Zitieren
APA
Morimoto, S., Kato, C., Takahashi, S., & Okano, H. (2026). Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy—Advances through 2026. Regenerative Therapy, 33, 101150. https://doi.org/10.1016/j.reth.2026.101150
Vancouver
Morimoto S, Kato C, Takahashi S, Okano H. Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy—Advances through 2026. Regenerative Therapy. 2026;33:101150. doi:10.1016/j.reth.2026.101150
BibTeX
@article{Morimoto2026,
author = {Morimoto, Satoru and Kato, Chris and Takahashi, Shinichi and Okano, Hideyuki},
title = {Therapeutic frontiers in ALS: iPSC-based drug discovery, cell therapy, and gene therapy—Advances through 2026},
journal = {Regenerative Therapy},
year = {2026},
volume = {33},
pages = {101150},
doi = {10.1016/j.reth.2026.101150}
}
EUVIMED